#1 Clinical Trials Search in Europe

Albiglutide

Clinical trials investigating Albiglutide are studying adults with type 2 diabetes. These trials look at how Albiglutide compares with other diabetes treatments and measure blood sugar control, especially HbA1c. The goal is to learn more about its effectiveness in people who need treatment for type 2 diabetes.

Table of contents

Trial overview

The clinical trial listed for Albiglutide is NCT05433584, an interventional study in adults with type 2 diabetes.[1] It is shown as Phase 3 and has a status of Authorised.[1] The planned enrollment is 781 participants.[1]

Who is being studied

This study is focused on adult participants with type 2 diabetes.[1] The trial data do not list the full eligibility rules, so the exact entry criteria are not available here.[1]

Study phase and design

The study is a Phase 3 trial, which usually means a larger study that compares treatment options and checks how well they work in real patient groups.[1] It is also described as an interventional study, meaning researchers are testing treatments and measuring the results.[1]

What is being measured

The main outcome is the change from baseline in hemoglobin A1c (HbA1c).[1] HbA1c is a blood test that shows average blood sugar over time, so it helps researchers see whether treatment improves diabetes control.[1] The study brief says the goal is to show that tirzepatide is non-inferior to intensified conventional care in HbA1c change from baseline to Week 104 in participants with type 2 diabetes.[1]

Treatments in the study

The intervention list includes Albiglutide at 50 mg by injection, along with several other diabetes medicines and treatment options used for comparison in the study.[1] These include sitagliptin, linagliptin, tirzepatide, semaglutide, exenatide, dulaglutide, liraglutide, lixisenatide, saxagliptin, pioglitazone, metformin, vildagliptin, and alogliptin, as well as some unnamed comparator entries in the trial record.[1]

What the trial aims to show

The trial record is centered on comparing treatment effects in type 2 diabetes, with HbA1c as the key measure of success.[1] For patients, this means the study is trying to learn whether the treatment strategy being tested can control blood sugar well over a long period, up to Week 104.[1]

Trial ID Phase Condition studied Status Enrollment
NCT05433584 Phase 3 Type 2 Diabetes Authorised 781

FAQ

  • What is being studied in Albiglutide clinical trials? The trial data show Albiglutide being used in a study of adults with type 2 diabetes. The main focus is blood sugar control, measured by HbA1c, which reflects average blood sugar over time.
  • Who may take part in these trials? The study includes adult participants with type 2 diabetes. The trial information does not list all eligibility rules, so exact participation depends on the study requirements.
  • What phase is the Albiglutide trial? The trial listed for Albiglutide is a Phase 3 study. Phase 3 trials are larger studies that compare treatments and help confirm how well a treatment works.
  • What condition is the trial focused on? The trial is focused on type 2 diabetes. This means the study is looking at treatment options for people whose blood sugar is too high because of this long-term condition.
  • What is the main outcome being measured? The main outcome is the change in HbA1c from the start of the study. This helps researchers see whether the treatment improves blood sugar control over time.

Ongoing Clinical Trials on Albiglutide

  • Evaluation of Long-Term Efficacy and Safety of Tirzepatide Versus Intensified Conventional Care in Early Treatment of Type 2 Diabetes in Adults

    Not yet recruiting

    1 1 1 1
    Investigated drugs:
    Czechia Germany Italy Romania Slovakia

Glossary

  • Type 2 diabetes: A long-term condition in which blood sugar stays too high. Clinical trials study treatments to help improve blood sugar control in adults with this condition.
  • Adult participants: People who are 18 years old or older and take part in a clinical study.
  • Phase 3: A later stage of clinical research with more participants. These studies compare treatments and help confirm how well they work.
  • Interventional study: A study where researchers give one or more treatments and then measure the results.
  • HbA1c: A blood test that shows average blood sugar over about 2 to 3 months. It is often used to measure diabetes control in clinical trials.
  • Baseline: The starting point before treatment begins. Changes from baseline show how much a result has changed during the study.
  • Non-inferior: A study result meaning one treatment is not worse than another by more than a set amount.
  • Week 104: A time point in a study that is 104 weeks, or about 2 years, after the start.
  • Enrollment: The number of people who are planned to join or have joined a study.

References